BRAF Immunohistochemistry Antibody

Detection of BRAF V600E Mutation in Tumor Tissues

The BRAF antibody by Talent Biomedical is a high-quality IHC reagent developed to detect BRAF protein expression and the BRAF V600E mutation in FFPE (formalin-fixed, paraffin-embedded) tumor samples.
This mutation leads to abnormal activation of the MAPK signaling pathway, promoting uncontrolled cell growth and tumor formation.
IHC detection of BRAF enables pathologists to determine mutation status, supporting accurate diagnosis and guiding targeted cancer therapies.

Fardad Azma Rad Co. – Authorized Distributor in Iran

Fardad Azma Rad is the exclusive representative of Talent Biomedical Technology Co., Ltd. (China) in Iran and the official supplier of BRAF and other advanced IHC antibodies.
With a focus on diagnostic accuracy, reliability, and international quality standards, the company provides high-performance reagents to pathology laboratories and cancer research centers across the country.

🔬 Features & Benefits

• Specifically detects BRAF V600E mutation in malignant tumors

• Produces clear cytoplasmic brown staining in positive cells

• Suitable for papillary thyroid carcinoma, melanoma, and colorectal adenocarcinoma

• Fully compatible with FFPE tissues and DAB-based IHC systems

• CE-IVD certified, manufactured under strict quality control

💡 Diagnostic Applications

• Detection of Papillary Thyroid Carcinoma (PTC)

• Identification of Melanoma and Colorectal Adenocarcinoma

• Assessment of BRAF expression in targeted therapy evaluation

• Research on MAPK pathway activation and BRAF gene mutations

“Download Brochure”